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Abstract 
Background: Quality of artemisinin-based combination therapy (ACT) is important for ensuring malaria parasite 
clearance and protecting the efficacy of artemisinin-based therapies. The extent to which non quality-assured ACT 
(non-QAACT), or those not granted global regulatory approval, are available and used to treat malaria in endemic 
countries is poorly documented. This paper uses national and sub-national medicine outlet surveys conducted in 
eight study countries (Benin, Kinshasa and Kantanga [Democratic Republic of the Congo, DRC], Kenya, Madagascar, 
Nigeria, Tanzania, Uganda and Zambia) between 2009 and 2015 to describe the non-QAACT market and to document 
trends in availability and distribution of non-QAACT in the public and private sector.
Results: In 2014/15, non-QAACT were most commonly available in Kinshasa (83%), followed by Katanga (53%), 
Nigeria (48%), Kenya (42%), and Uganda (33%). Non-QAACT accounted for 20% of the market share in the private 
sector in Kenya, followed by Benin and Uganda (19%), Nigeria (12%) and Zambia (8%); this figure was 27% in Katanga 
and 40% in Kinshasa. Public sector non-QAACT availability and distribution was much lower, with the exception of 
Zambia (availability, 85%; market share, 32%). Diverse generics and formulations were available, but non-QAACT were 
most commonly artemether–lumefantrine (AL) or dihydroartemisinin-piperaquine (DHA PPQ), in tablet formulation, 
imported, and distributed in urban areas at either pharmacies or drug stores. The number of unique manufacturers 
supplying non-QAACT to each country ranged from 9 in Uganda to 92 in Nigeria.
Conclusions: Addressing the availability and distribution of non-QAACT will require effective private sector engage-
ment and evidence-based strategies to address provider and consumer demand for these products. Given the varia-
tion in non-QAACT markets observed across the eight study countries, active efforts to limit registration, importation 
and distribution of non-QAACT must be tailored to the country context, and will involve addressing complex and 
challenging aspects of medicine registration, private sector pharmaceutical regulation, local manufacturing and drug 
importation. These efforts may be critical not only to patient health and safety, but also to effective malaria control 
and protection of artemisinin drug efficacy in the face of spreading resistance.
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Background
The consequences and dangers of poor quality anti-
malarials are extensive. They contributed to an esti-
mated 91,577–154,736 deaths among African children 
under the age of five alone in 2013 [1]. Poor quality anti-
malarials containing sub-therapeutic doses of the active 
pharmaceutical ingredient (API) may be ineffective at 
clearing malaria parasites, leading to prolonged illness or 
even patient death. Additional undisclosed ingredients 
could pose an independent threat to consumer health or 
could interact adversely with a patient’s existing medica-
tion regimen. Aside from causing morbidity and mortal-
ity, poor quality artemisinin combination therapy (ACT) 
medicines—the recommended first-line treatment for 
uncomplicated malaria in sub-Saharan Africa (SSA)—
waste consumer money and may decrease confidence 
among consumers and providers in the efficacy of ACT. 
Poor quality anti-malarials are also critical to effective 
malaria control and protection of artemisinin and part-
ner drug efficacy given their use can promote drug resist-
ance [2–5]. In particular, the emergence of artemisinin 
resistance, likely resulting from decades of sub-thera-
peutic monotherapy and substandard artemisinin deriva-
tive consumption [6], has prompted increased attention 
to anti-malarial medicine quality in recent years. Medi-
cine quality is one of the many threats to appropriate and 
effective malaria case management, along with other fac-
tors such as lack of or incorrect parasitological diagno-
sis, use of non-artemisinin therapies, insufficient access 
to quality-assured ACT (QAACT), and poor medication 
adherence by consumers [3, 4]. Nonetheless, the pres-
ence of potentially poor quality anti-malarials in the mar-
ket is clearly a key cause for concern in the fight against 
malaria.
Poor quality anti-malarials include substandard and 
falsified medicines. The term ‘substandard’ refers to 
medicines that may not contain the indicated amount of 
API and/or may have poor dissolution of the API [5, 7]. 
Substandard drugs include both poorly manufactured 
medicines, and degraded medicines whose contents and 
therapeutic value were negatively affected during stor-
age or distribution by extreme temperature or time. The 
compromised quality of these substandard and degraded 
drugs is a result of failures in quality monitoring along 
production and supply chains. In contrast, falsified anti-
malarials are produced fraudulently and labeling con-
tains false claims on content and origin. These medicines 
may contain little or none of the claimed API, and may 
include incorrect, unstated substances [7].
In SSA, where 90% of the global malaria mortality 
burden is concentrated [8], a major barrier to address-
ing poor quality anti-malarials is gauging the extent of 
the problem. A number of anti-malarial drug quality 
studies have been conducted in recent years [9]. These 
studies involve sampling and testing active ingredi-
ents and have been useful in providing some indication 
of the extent to which poor quality anti-malarials are 
available. In recent ACT drug quality studies in SSA, 
between 0.3 and 66.7% of drugs studied were found to 
be outside the acceptable API range [3, 10–16]. In a 
review of falsified and substandard medicines, eight 
prevalence estimates from sub-Saharan Africa ranged 
from 12.2 to 48%, with a median of 34.5% [17]. However, 
such anti-malarial quality studies tend to be conducted 
on a sub-national scale and use convenience sampling, 
small sample sizes, and variable techniques for chemi-
cal quality analysis  [3, 5, 7, 18, 19]. While this evidence 
on poor quality anti-malarials has been aggregated in 
databases such as the WorldWide Anti-malarial Resist-
ance Network’s (WWARN) Anti-malarial Quality map 
[9], the variation in individual study methodologies 
makes identifying trends and generalization beyond 
study settings challenging. Thus, it has been difficult to 
determine the scale of the problem in high malaria bur-
den countries due to the lack of available standardized 
and comprehensive data with which to characterize the 
market for poor quality medicines  [4]. As the majority 
of anti-malarials in SSA countries are distributed by the 
private sector, understanding this market and improv-
ing private provider practices related to quality-assur-
ance is essential [20].
At the global level, one strategy for ensuring avail-
ability and use of quality anti-malarials is medicine pre-
qualification. Prequalification programs are designed to 
identify medicines that are manufactured according to 
quality standards yielding safe and efficacious medicines. 
Approval through these mechanisms varies, but typically 
requires the manufacturer to submit an application, doc-
umentation of the chemical and pharmaceutical prop-
erties of the product, bioequivalence tests (if generic), 
package labeling, proof of in-country registration, and 
a record of facilities’ good manufacturing processes, for 
review by a panel of experts  [21–25]. Depending on the 
reviewer body, applicants may also be required to pay a 
processing fee [23–26]. Anti-malarials designated as pre-
qualified or granted regulatory approval by global author-
ities such as the World Health Organization (WHO), may 
be considered “quality-assured” (Fig. 1). This quality des-
ignation has been leveraged to promote private sector 
distribution of quality anti-malarials by the Global Fund’s 
Private Sector Copayment Mechanism, first piloted in 
2010–2011 as the Affordable Medicines Facility-malaria 
(AMFm), by facilitating first-line buyer access to afford-
able quality-assured medicines [27].
Malaria-endemic countries in SSA have limited 
resources at the country level for evaluating the safety and 
Page 4 of 21ACTwatch Group et al. Malar J  (2017) 16:204 
efficacy of anti-malarials and implementing regulatory 
processes [21, 23]. As such, global medicine pre-qualifi-
cation is an essential tool for ensuring that medicines cir-
culating in the global marketplace are of high quality. The 
World Health Organization’s Prequalification Program 
(WHO PQP), developed in 2001, serves as a global reg-
ulator. Using the Good Manufacturing Practices (GMP) 
defined by the World Health Assembly in the 1960s as a 
foundation, the WHO PQP aims to identify medicines 
that meet “unified standards for quality, safety, and effi-
cacy”. The programme employs a rigorous review and 
approval process to qualify medicines and products for 
procurement by U.N. agencies. In doing so, the WHO 
PQP seeks to standardize international drug quality and 
ensure access to priority essential medicines [28]. Other 
entities, such as the Global Fund and the European Medi-
cines Agency (EMA) have developed their own, some-
times complementary, processes to approve medicines 
for global market entry [29, 30] (Fig. 2). WHO PQP sta-
tus is often viewed as a global standard for drug quality, 
especially since organizations like the Global Fund use 
the WHO PQP list as a base to form approved product 
procurement lists.
GMP and quality-assurance status granted by regula-
tory authorities do not necessarily preclude manufactur-
ing quality failures or prevent conditions or practices that 
may lead to drug degradation over time. Moreover, medi-
cines that have not been granted pre-qualification status 
or regulatory approval may be safe and efficacious. None-
theless, quality-assurance status has been associated with 
high quality medicines in field drug quality studies  [31]. 
A nationally representative survey of over 1700 anti-
malarials in Tanzania’s private sector found that ACT 
samples lacking WHO prequalification were 25 times 
more likely to be of poor quality than those with WHO 
prequalification status  [14]. When adjusting for date of 
expiry among ACT, lack of WHO prequalification was 
the strongest predictor of poor quality in a multivariate 
analysis. The results of this study highlight that quality-
assurance status can serve as an important indicator of 
ACT drug quality.
This paper uses data from 29 malaria medicine out-
let surveys conducted under the ACTwatch project 
between 2009 and 2015 in eight country contexts (Benin, 
Quality-assured ACT Non quality-assured ACT
Not quality-
assured according 
to the criteria
Medicines are either:
• WHO Pre-qualified
• In compliance with the 
Global Fund Quality-
Assurance Policy and on 
the Global Fund list of 
approved products for 
procurement
• Granted regulatory 
approval by
Fig. 1 Defining QAACT and non-QAACT
Paths to Obtaining Quality-Assured Status
Prequalificaon from WHO or  authorizaon from a stringent regulatory authority
Centralized Route: Submission of a 
single markeng-authorizaon 
applicaon for a product
Scienfic assessment of the 
applicaon 
Decision to allow product to enter the 
market throughout the EU, and in Iceland, 
Norway, and Lichtenstein
WHO 
PQP 
(meline: 
minimum 3 
months)
Quality-
assured 
medicine 
status
Global 
Fund
European 
Medicines 
Agency
Naonal Route: Authorizaon of medicines by EU member state prior to creaon of 
EMA (or when medicine is out of the scope of the EMA’s centralized procedure)
Inspecon of 
manufacturing 
sites
Decision to place the
product on the WHO list of 
prequalified medicines (if 
accepted, product maintenance 
is conducted periodically)
Invitaon to 
manufacturers to 
submit an expression 
of interest (EOI) for 
specific products
Submission of dossiers 
by manufacturers; 
assessment by WHO 
staff and regulatory 
experts
Invitaon to manufacturers to 
submit an EOI for specific 
products that are eligible for 
short-term approval by an ERP 
(expert review panel)
Review of regulatory status 
of the manufacturer/facility, 
pharmacopoeia compliance, 
product safety and efficacy 
data 
Submission of 
dossiers by 
manufacturers; 
assessment by ERP 
staff and 
regulatory experts
Fig. 2 Paths to obtaining quality assured status
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Kinshasa and Katanga in the Democratic Republic of 
Congo [DRC], Kenya, Madagascar, Nigeria, Tanzania, 
Uganda, and Zambia) to examine the extent to which 
non-QAACT are available and distributed to consumers. 
ACT were classified as quality-assured or non quality-
assured according to approval status by the WHO pre-
qualification programme, the Global Fund, or the EMA 
(see Fig. 1 for quality classification criteria and Fig. 2 for 
the drug approval processes by entity). During the study 
time period, four of the study countries (Kenya, Nige-
ria, Uganda and Tanzania) saw growth in private sector 
availability and distribution of QAACT due to the Private 
Sector Copayment Mechanism [27]. Given this evidence, 
this study also examines availability and market share for 
non-QAACT in contexts with and without large-scale 
private sector market interventions to improve access to 
QAACT.
Methods
ACTwatch was launched in 2008 with the goal to gen-
erate timely, relevant and high quality evidence about 
anti-malarial markets for policy makers, donors and 
implementing organizations. Both supply and demand 
sides of the anti-malarial market were addressed, through 
outlet and household surveys, supply chain analysis, key 
informant interviews and exit interviews for consumers 
of anti-malarial-stocking outlets. As of 2016, ACTwatch 
had gathered data from 12 malaria endemic countries in 
sub-Saharan Africa and the Greater Mekong sub-Region. 
Detailed ACTwatch project and methodological informa-
tion have been published elsewhere  [32, 33].
Design and sampling
ACTwatch outlet surveys were nationally-representative 
(with the exception of the sub-national surveys in the 
DRC), cross-sectional quantitative surveys conducted 
among a sample of outlets stocking anti-malarials. Sur-
veys were repeated over time to inform, monitor and eval-
uate policies and strategies designed to improve access 
and use of malaria diagnostics and first-line treatments.
All categories of outlets with the potential to stock 
anti-malarials in both the public/not-for-profit and pri-
vate-for-profit sector were included in the study. In the 
public/not-for-profit sector (hereafter referred to as sim-
ply the ‘public sector’), this included government and 
non-government not-for-profit health facilities (hospi-
tals, centers, clinics and posts) and community health 
workers. Outlets sampled in the private sector included 
private for-profit health facilities (hospitals, centers and 
clinics), pharmacies, drug stores (registered/regulated 
and unregistered/unregulated), general retailers selling 
fast-moving consumer goods, and itinerant drug vendors 
(mobile vendors without a fixed service delivery point).
Lists of all potentially eligible outlets were not routinely 
available and therefore a cluster sampling approach with 
an outlet census was used to identify outlets for inclu-
sion. Clusters were administrative units ideally with 
a typical size of 10,000–15,000 inhabitants, and were 
selected using probability proportional to population size 
(PPS) sampling. Within each selected cluster all outlets 
with the potential to provide anti-malarials to consumers 
were screened for eligibility. Outlets were eligible for an 
anti-malarial product audit if they had one or more anti-
malarials in stock on the survey day.
Boundaries for the outlet census were typically 
extended to higher administrative units to cover a larger 
area for the census of public health facilities and pharma-
cies, in order to over-sample these relatively uncommon 
but important outlet types.
Each survey was stratified to deliver estimates for rele-
vant research domains: all countries had urban and rural 
stratification, with the exception of Nigeria for which 
six geopolitical zones were used as research domains. 
Each study round was powered to detect a minimum 
of a 20% point change in availability of QAACT among 
anti-malarial stocking outlets between each round and 
within each domain at the 5% significance level with 80% 
power. The number of study clusters was calculated for 
each research domain based on the required number of 
anti-malarial stocking outlets and assumptions about 
the number of anti-malarial stocking outlets per cluster. 
Sample size requirements for follow-up surveys were cal-
culated using information from previous survey rounds 
including anti-malarial and QAACT availability, outlet 
density per cluster, and design effect.
Data collection periods varied by country and over 
time but were typically implemented during the peak 
malaria transmission season for each country and lasted 
6–8  weeks. Efforts were made to ensure surveys were 
implemented over similar time points across the survey 
rounds.
Training and fieldwork
Interviewer training consisted of standardized classroom 
presentations and exercises as well as a field exercise. 
Exams administered during training were used to select 
data collectors, supervisors, and quality-controllers. 
Additional training was provided for supervisors and 
quality-controllers focused on field monitoring, verifica-
tion visits, and census procedures. Data collection teams 
were provided with a list of selected clusters and official 
maps that illustrated their administrative boundaries. In 
each selected cluster, fieldworkers conducted a full enu-
meration of all outlets that had the potential to provide 
anti-malarials. This included enumeration of outlets with 
a physical location, as well as identification of community 
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health workers and itinerant drug vendors using local 
informants and snowball sampling. The primary pro-
vider/owner of each outlet was invited to participate in 
the study and screening questions were administered 
to assess anti-malarial availability. Interviews were con-
ducted in local language(s) and questionnaires under-
went forward and backward translation from English 
to the local language. Quality control measures imple-
mented during data collection included questionnaire 
review by supervisors and a minimum of 10% of outlets 
were back-checked.
Measures
The outlet survey questionnaire included an audit of all 
available anti-malarials. Providers were asked to show the 
interviewer all anti-malarials currently available. A prod-
uct audit sheet captured information for each unique 
anti-malarial product in the outlet, including formula-
tion, brand name, active ingredient(s) and strength(s), 
package size, manufacturer and country of manufacture. 
Providers were asked to report the retail and wholesale 
cost for each medicine, as well as the amount distrib-
uted to individual consumers in the last week. All sur-
veys were paper-based with the exception of Madagascar 
in 2015 and Uganda in 2015, where data were collected 
using Android phones and forms created using DroidDB 
(© SYWARE, Inc., Cambridge, MA, USA).
Protection of human subjects
The outlet survey protocols received ethical approval 
from national ethical approval boards within each coun-
try and for each survey round. Ethical clearance for the 
last survey round was as follows: DRC, ESP/CE/096/2015; 
Kenya, KNH-ERC/A/360; Madagascar, 090-MSANP/
CE; Nigeria, NHREC/01/01/2007-09/07/2015; Tanza-
nia, NIMR/HQ/R.8a/Vol. IX/1840; Uganda, 2008-057; 
Zambia, IRB00001131. Provider interviews and prod-
uct audits were completed only after administration of 
a standard informed consent form and provider consent 
to participate in the study. Providers had the option to 
end the interview at any point during the study. Standard 
measures were employed to maintain provider confiden-
tiality and anonymity, such as ensuring privacy during 
interviews, securing storage of completed questionnaires, 
and preventing any sharing of data between outlets [32].
Data analysis
Double data entry was conducted using Microsoft Access 
(Microsoft Corporation, Redmond, WA, USA) with built-
in range and consistency checks. Data were analyzed 
across survey rounds using Stata Version 13.1 (StataCorp 
College Station, TX, USA).
Standard indicators were constructed according 
to definitions applied across the ACTwatch project 
described elsewhere [20, 33]. Anti-malarials identified 
during the outlet drug audit were classified according 
to information on drug formulation, active ingredients 
and strengths as non-artemisinin therapies, artemisinin 
monotherapies and ACT. ACT were classified as 
QAACT or non-QAACT, with the former including 
products meeting one of three criteria: (1) the product 
had WHO PQP status; (2) the product was in compli-
ance with the Global Fund quality assurance policy and 
appears on the Global Fund list of approved products 
for procurement; or (3) the product was granted regu-
latory approval by the EMA. Products were matched to 
each of these lists across the categories of formulation, 
active ingredients, strength, manufacturer, country of 
manufacture, and package size. ACT that met all these 
conditions were classified as quality-assured ACT. Prod-
ucts that did not match all criteria were categorized as 
non-QAACT.
Availability was defined as the presence of one or 
more anti-malarials at the outlet at the time of the sur-
vey. The availability of specific anti-malarial categories 
was restricted to those outlets that had anti-malarials in 
stock. The availability of non-QAACT was measured as 
the proportion of outlets stocking non-QAACT, among 
all outlets with at least one anti-malarial in stock. Sig-
nificant differences in non-QAACT availability levels 
between baseline year and most recent survey year in 
each country were estimated using logistic regression 
with survey settings, with a binary dependent vari-
able for availability of non-QAACT at the outlet level, 
and a dummy independent variable for year. Types of 
non-QAACT found in the public and private sector 
were described using descriptive statistics for product 
information, including product generic name, formula-
tion, country of manufacture, and national registration 
status.
The sales or distribution of the anti-malarials recorded 
in the drug audit were standardized using the adult 
equivalent treatment dose (AETD) to allow meaning-
ful comparisons between anti-malarials with different 
treatment courses. The AETD is defined as the amount 
of active ingredient required to treat an adult weighing 
60  kg according to WHO treatment guidelines. Median 
private sector price for one AETD was calculated for 
non-QAACT and for QAACT. The interquartile range 
(IQR) is displayed as a measure of dispersion. Price data 
presented were collected in local currencies and deflated 
to 2009 prices using national consumer price indices. 
Price data were converted to US dollars using official 
exchange rates for the data collection period obtained 
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from http://www.oanda.com. Price measures included 
tablet anti-malarials only, given differences in unit costs 
for tablet and non-tablet formulations. While all QA 
ACT are by definition tablet formulation, non-QAACT 
are also available in non-tablet formulations, most com-
monly suspensions. The median price for one bottle for 
suspension formulation is also reported.
Provider reports on the amount of the drug sold or 
distributed during the week preceding the survey were 
used to calculate sales volumes according to type of 
anti-malarial. The volume of each drug is, therefore, 
the number of AETDs that were reportedly sold/dis-
tributed during the week preceding the survey. Meas-
ures of volume include all dosage forms to provide a 
complete assessment of anti-malarial market shares 
to the consumer or patient. Additional public health 
facilities and pharmacies sampled as part of over-
sampling for these outlet types were not included in 
market share calculations. The statistical significance 
of differences in market share of non-QAACT was 
estimated using Stata’s ratio command, with survey 
settings, and the post-estimation ‘lincom’ (linear com-
bination) command.
Sampling weights were calculated as the inverse of 
the probability of cluster selection. All point estimates 
were weighted using survey settings and all stand-
ard errors were calculated taking account of the clus-
tered and stratified sampling strategy with Stata survey 
commands.
Results
A total of 200,509 outlets were screened to assess avail-
ability of anti-malarials across the eight country con-
texts (Benin, Kinshasa and Katanga, Kenya, Madagascar, 
Nigeria, Tanzania, Uganda, and Zambia) and 29 survey 
rounds between 2009 and 2015 (Table  1). An audit of 
all available anti-malarial medicines was completed in 
49,554 eligible outlets. In total, 336,017 anti-malarials 
were audited, including 78,558 QAACT and 83,130 non-
QAACT. A catalogue of all the non-QAACT products 
audited can be found in Additional file 1.
Availability of quality‑assured and non‑QAACT
Figures 3 and 4 illustrate the availability of QAACT and 
non-QAACT in public and private sector anti-malarial 
stocking outlets. Non-QAACT availability in the public 
sector decreased significantly over time in Benin (2009, 
17.4%; 2014, 0.5%; p  <  0.001), Katanga (2013, 25.5%; 
2015, 11.3%; p < 0.01), Uganda (2010, 25.5%; 2015, 1.5%; 
p  <  0.001) and Madagascar (2010, 14.2%; 2015, 1.5%; 
p < 0.01) (Fig. 3). At the time of the most recent survey, 
availability was also relatively low in Tanzania (7.0%), 
Kenya (14.0%) and Nigeria (21.1%). Availability was high 
in Kinshasa (39.3%) in 2015, representing a significant 
increase from 20.0% in 2009 (p < 0.05). Availability was 
notably highest in Zambia at 85.1% in 2014, representing 
a significant increase from 5.1% in 2009 (p < 0.001). 
Non-QAACT availability in the private sector 
increased significantly over time in Kinshasa (2009, 
60.7%; 2015, 82.8%; p  <  0.001), Nigeria (2009, 23.2%; 
2015, 48.0%; p  <  0.01), and Kenya (2010, 21.0%; 2015, 
41.6%; p  <  0.001) (Fig.  4). Availability decreased signifi-
cantly in Uganda from 52.0% in 2010 to 37.8% in 2015 
(p  <  0.05). Private sector availability of non-QAACT 
varied substantially between countries during the most 
recent survey round from 0% in Madagascar and 4.0% in 
Benin, to 16.9% in Zambia, 20.6% in Tanzania, and 37.8% 
in Uganda. More than 40% of private sector outlets were 
stocking non-QAACT in Kenya (41.6%), and about half 
of outlets had non-QAACT in stock in Nigeria (48.0%) 
and Katanga (52.7%). Availability was 82.8% in Kinshasa.
Overall, QAACT availability was substantially higher 
than non-QAACT availability in the public and pri-
vate sectors, particularly during the most recent survey 
round. Exceptions include Zambia, where availability 
of QAACT and non-QAACT was similar in 2014 in the 
public sector (QAACT, 89.8%; non-QAACT, 85.1%) and 
the private sector (QAACT, 20.8%; non-QAACT, 16.9%), 
and in Katanga where private sector availability was simi-
lar in 2015 (QAACT, 52.0%; non-QAACT, 52.7%). In Kin-
shasa, private sector non-QAACT availability has been 
substantially higher than QAACT availability across sur-
vey rounds. In 2015 QAACT availability was only 22.4% 
compared to 82.8% for non-QAACT.
Characteristics of non‑QAACT available in the public 
and private sector in the most recent survey round
Tables  2 and 3 describe public sector and private sec-
tor non-QAACT product information in studies with at 
least 25 non-QAACT audited within the sector. Across 
survey country contexts, nine different generic non-
QAACT were audited in the public and private sector. 
The most common non-QAACT audited in both sec-
tors in most countries was artemether-lumefantrine 
(AL). Dihydroartemisinin–piperaquine (DHA PPQ) was 
also common in certain countries, and in the public and 
private sectors in Kenya, Tanzania and Uganda, DHA 
PPQ was as common, or more common than AL. The 
majority of non-QAACT audited were tablet formula-
tion across countries and sectors. However, suspensions 
were also common, accounting for approximately half 
or more of the audited products in the public sector in 
Kinshasa (68.7%) and Nigeria (45.8%), and about one-
third of the products in the private sector in Kinshasa 
(39.8%), Katanga (33.9%), Nigeria (35.8%) and Kenya 
(30.4%). 
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Non-QAACT were usually imported from other 
countries, although local manufacturing accounted for 
approximately one-quarter of audited products in the 
public and private sectors in Kinshasa (25.6% and 24.8%, 
respectively) and Katanga (23.7, 29.2% respectively). 
Products imported from India accounted for the major-
ity of audited non-QAACT in both the public and private 
sectors in most countries, with the exception of a high 
proportion of products imported from China in Tanza-
nia’s public and private sectors, and in Uganda’s public 
sector.
In total, over 180 unique manufacturers were identi-
fied. The number of unique manufacturers with more 
than one non-QAACT product audited in each country 
setting was as follows: Benin, 42; DRC, 45; Nigeria, 92; 
Kenya, 24; Tanzania, 19; Uganda, 9; Zambia, 16. In con-
trast, the number of unique manufacturers for quality-
assured ACT audited in each country was considerably 
lower: Benin, 7; DRC, 6; Nigeria, 7; Kenya, 7; Tanzania, 6; 
Uganda, 7; Zambia 5.
The extent to which audited non-QAACT were regis-
tered by the national drug regulatory authority (NDRA) 
varied by country and sector. Half or more of audited 
non-QAACT in the most recent survey were registered 
with a NDRA in the public and private sectors of Nige-
ria (48.5, 60.5% respectively) and Uganda (63.2, 89.6% 
respectively), in the public sector in Kinshasa (52.8%), 
and in the private sector in Katanga (53.1%), Kenya 
(64.7%) and Zambia (79.5%). Notably, the ACT procured 
and made widely available in the public sector in Zambia 
Table 1 Results of the outlet census and anti-malarial audit by country and survey year
Country Year Screened  
(N outlets)
Anti‑malarial audit  
completed (N outlets)
Anti‑malarials audited  
(N drugs)
QAACT audited  
(N drugs)
Non‑QAACT 
audited (N drugs)
West and Central Africa
 Benin 2009 1670 844 5233 859 1629
2011 2891 1237 8987 1396 3925
2014 4332 1806 14,378 2483 6454
 DRC, Kinshasa 2009 2368 766 8437 151 1911
2013 3364 931 12,291 216 6022
2015 1168 1056 16,287 853 7389
 DRC, Katanga 2013 2270 771 6493 854 1975
2015 1052 993 8050 1507 2025
 Nigeria 2009 5456 2113 20,841 1192 4624
2011 7938 1486 13,391 2119 1610
2013 5148 1714 14,358 4799 2058
2015 13,483 3473 33,539 9586 7173
East Africa
 Kenya 2010 13,897 1888 8376 2052 2276
2011 11,383 1854 9544 3669 2153
2014 12,676 2133 9899 3234 3133
 Tanzania 2010 3120 624 5544 416 1415
2011 3702 787 9701 2045 2300
2014 4724 2129 17,307 4905 2314
 Uganda 2010 11,153 2410 14,427 2893 3785
2011 16,207 3138 20,283 5495 4683
2013 7932 3307 19,777 7182 4314
2015 9438 4328 26,640 7380 7238
Southern Africa
 Madagascar 2010 6769 2414 5579 1790 184
2011 10,046 2360 7234 3233 172
2013 10,149 1756 6101 3851 116
2015  13,481  1040  3170 1501 4
 Zambia 2009 3378 435 1783 601 158
2011 5436 781 3355 1036 594
2014 5878 980 5012 1260 1496
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(AL manufactured by S  Kant.) was not found on the 
NDRA registration list.
Price of QAACT and non‑QAACT
Figure  5 summarizes the median private sector price 
for one AETD for tablet formulation of quality-assured 
and non quality-assured AL, and suspension formula-
tion of non quality-assured AL. Price is reported for 
AL, given that AL is a national first-line treatment 
and was the most common ACT audited within each 
country.
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Fig. 3 Availability of QAACT and non-QAACT in the public sector. Significant difference in non-QAACT availability between first and final survey 
year: *p < 0.05, **p < 0.01, ***p < 0.001
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The median private sector price for non quality-assured 
AL tablets was from 1.3 (Uganda) to 3 (Tanzania) times 
higher than the price of quality-assured AL in all countries 
with the exception of Kinshasa, where quality-assured AL 
was 1.7 times more expensive than non quality-assured 
AL. Similarly, the price of one bottle of non quality-assured 
AL AETD suspension was between 1.8 (Nigeria) to 6.5 
(Tanzania) times more expensive than one quality-assured 
AL AETD in all countries except Kinshasa where one qual-
ity-assured AL AETD was 2 times more expensive than 
one bottle of non quality-assured AL suspension.
The differences in price of quality-assured and non-
QAACT for generics other than AL followed a similar 
pattern, whereby non-QAACT tablets and suspensions 
were more expensive than quality-assured tablets in each 
country (Additional file 2).
Table 2 Characteristics of non-QAACT available in the public sector during the most recent survey round
Countries excluded include: Benin (n = 18 products) and Madagascar (n = 4 products)
n/a Registration list not available in Tanzania for 2014
a  Excluding products with unknown country of manufacture
b  Kinshasa: Vietnam; Katanga: Morocco; Nigeria: Morocco, Pakistan
Kinshasa, DRC 
2015
Katanga DRC 
2015
Nigeria 2015 Kenya 2014 Tanzania 2014 Uganda 2015 Zambia 2014
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
N = 390 N = 148 N = 96 N = 50 N = 58 N = 59 N = 941
Active ingredients (type)
 Artemether lume-
fantrine
75.0 (69.9–79.5) 76.8 (66.1, 84.9) 76.2 (52.7, 90.2) 44.2 (23.4, 67.3) 52.6 (33.1, 71.4) 37.6 (22.1, 56.2) 100.0 (99.8, 100.0)
 Artesunate amo-
diaquine
4.9 (3.1, 7.9) 10.5 (3.9, 25.3) 8.3 (1.6, 33.0) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–)
 Artesunate meflo-
quine
0.0 (–) 0.0 (–) 0.3 (<0.1, 2.2) 0.3 (0.1, 1.0) 5.0 (1.2, 18.0) 0.0 (–) 0.0 (–)
 Artemisinin 
piperaquine
1.2 (0.3, 4.5) 1.6 (0.5, 4.9) 0.0 (–) 6.4 (2.8, 13.9) 2.5 (1.0, 6.3) 0.0 (–) 0.0
 Artemisinin naph-
thoquine
0.9 (0.1, 6.1) 0.0 (–) 0.0 (–) 6.2 (2.6, 13.9) 0.0 (–) 19.0 (7.7, 39.7) 0.0 (–)
 Artesunate SP 5.1 (3.3, 7.9) 5.5 (2.9, 10.3) 3.2 (0.5, 18.8) 0.8 (0.2, 3.0) 0.0 (–) 0.0 (–) 0.1 (<0.1, 0.2)
 Dihydroarte-
misinin pipe-
raquine
12.1 (8.2, 17.3) 2.1 (0.9, 4.7) 12.0 (4.4, 28.7) 42.1 (26.1, 59.9) 39.9 (22.0, 61.0) 43.0 (26.1, 61.6) 0.0 (–)
 Dihydroarte-
misinin SP
0.8 (0.4, 1.8) 3.5 (0.9, 12.3) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–)
 Arterolane pipe-
raquine
0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–) 0.4 (0.1, 2.6) 0.0 (–)
Product formulation
 Tablet 56.5 (48.0, 64.7) 70.0 (61.4, 77.3) 61.0 (41.9, 77.2) 77.1 (64.5, 86.2) 91.5 (78.6, 96.9) 87.3 (74.7, 94.1) 99.6 (99.0, 99.8)
 Suspension 43.5 (35.3, 52.0) 30.0 (22.7, 38.6) 38.1 (22.1, 57.2) 22.9 (13.8, 35.5) 7.6 (2.6, 20.1) 12.8 (5.9, 25.3) 0.4 (0.2, 1.0)
 Granule 0.0 (–) 0.0 (–) 0.9 (0.1, 7.0) 0.0 (–) 0.9 (0.1, 5.6) 0.0 (–) 0.0 (–)
N = 384 N = 145 N = 96 N = 50 N = 54 N = 59 N = 939
Country of  manufacturea
 Local 25.6 (19.8, 32.4) 23.7 (15.9, 33.7) 17.1 (5.2, 43.5) 14.8 (7.1, 28.2) 1.1 (0.2, 6.6) 0.0 (–) 0.0 (–)
 India 62.7 (57.2, 67.8) 69.7 (59.7, 78.1) 61.5 (42.8, 77.3) 58.8 (40.5, 75.0) 35.3 (18.2, 57.2) 37.7 (21.9, 56.5) 99.9 (99.7, 100.0)
 China 2.4 (0.9, 6.6) 1.8 (0.6, 5.7) 19.0 (7.9, 39.0) 16.7 (8.7, 29.5) 47.3 (27.7, 67.7) 54.1 (33.9, 73.0) 0.0 (–)
 European Country 3.4 (2.0, 5.6) 2.9 (1.3, 6.4) 0.3 (< 0.1, 2.2) 9.7 (5.5, 16.6) 16.3 (6.4, 35.6) 8.3 (2.8, 22.0) 0.1 (< 0.1, 0.4)
 Otherb 6.0 (2.7, 12.8) 1.9 (0.4, 9.3) 2.2 (0.4, 12.1) 0.0 (–) 0.0 (0) 0.0 (–) 0.0 (–)
 Registered with the 
National Drug Regulatory 
Authority
52.8 (44.0, 61.4) 19.3 (13.2, 27.2) 48.5 (26.9, 70.6) 33.6 (21.5, 48.2) n/a 63.2 (43.5, 79.2) 1.6 (0.9, 3.0)
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Table 3 Characteristics of non-QAACT available in the private sector during the most recent survey round
Benin 2014 Kinshasa, DRC 
2015
Katanga, DRC 
2015
Nigeria 2015 Kenya 2014 Tanzania 
2014
Uganda 2015 Zambia 2014
% (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
N = 6436 N = 6999 N = 1877 N = 7077 N = 3083 N = 2255 N = 7179 N = 555
Active ingredients (type)
Artemether 
lumefantrine
64.9 (61.6, 68.1) 67.0 (64.8, 69.2) 75.1 (68.0, 81.1) 65.8 (62.4, 69.0) 40.3 (36.5, 44.2) 29.0 (24.7, 33.7) 52.5 (48.5, 56.4) 75.4 (66.4, 82.6)
Artesunate 
amodiaquine
1.4 (1.0, 2.1) 3.8 (3.1, 4.6) 3.7 (2.9, 4.9) 5.5 (3.7, 8.1) 0.3 (0.2, 0.5) 0.2 (0.1, 0.3) 0.3 (0.1, 1.0) 1.1 (0.2, 7.5)
Artesunate 
mefloquine
5.5 (4.3, 7.1) 0.5 (2.6, 0.8) <0.1 (<0.1, 0.2) 1.4 (0.7, 2.8) 2.8 (2.2, 3.6) 8.2 (5.7, 11.5) 1.1 (0.8, 1.7) 0.0 (–)
Artemisinin 
piperaquine
0.2 (0.0, 0.8) 1.4 (0.9, 2.1) 1.5 (0.6, 3.5) 0.8 (0.4, 1.6) 8.5 (7.9, 9.3) 19.3 (16.5, 22.4) 0.0 (–) 0.0 (–)
Artemisinin 
naphthoquine
1.1 (0.7, 1.5) 0.0 (–) 0.0 (–) 0.0 (–) 2.3 (1.9, 2.7) 1.7 (0.6, 4.6) 6.7 (5.4, 8.3) 0.7 (0.3, 1.5)
Artesunate SP 8.6 (7.6, 9.7) 9.7 (8.6, 10.8) 7.3 (4.0, 13.0) 1.6 (1.1, 2.4) 3.3 (2.6, 4.1) 0.0 (–) 0.0 (–) 21.2 (14.1, 30.5)
Dihydroar-
temisinin 
piperaquine
11.7 (9.2, 14.6) 14.6 (13.4, 15.8) 5.1 (3.8, 6.8) 24.7 (22.7, 46.7) 42.2 (40.0, 44.9) 41.7 (37.9, 45.7) 39.1 (36.0, 42.2) 1.6 (14.1, 30.5)
Dihydroar-
temisinin 
piperaquine 
trimethoprim
3.4 (2.9, 3.9) 0.2 (0.1, 0.5) 0.0 (–) 0.1 (<0.1, 0.2) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–)
Dihydroarte-
misinin SP
3.3 (2.6,4.3) 2.9 (2.5, 3.3) 7.2 (6.3, 8.2) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–) 0.0 (–)
Arterolane pipe-
raquine
0.0 (–) 0.0 (–) 0.0 (–) 0.2 (0.1, 0.4) 0.0 (–) 0.0 (–) 0.3 (0.1, 0.5) 0.0 (–)
Product formulation
 Tablet 71.2 (68.3, 74.0) 60.2 (57.5, 62.8) 66.1 (63.9, 68.1) 60.8 (57.3, 64.2) 68.5 (66.2, 70.7) 86.4 (82.9, 89.2) 74.7 (71.3, 77.9) 74.3 (67.5, 80.1)
 Suspension 25.3 (23.8, 26.9) 39.8 (37.2, 42.5) 33.9 (31.8, 36.1) 35.8 (31.9, 39.9) 30.4 (28.1, 32.9) 13.6 (10.8, 17.0) 25.2 (22.0, 28.6) 25.7 (19.9, 32.5)
 Granule or  
suppository
3.5 (1.5, 7.9) <0.1 (<0.1, 0.2) <0.1 (<0.1, 0.2) 3.4 (2.6, 4.5) 1.1 (0.8, 1.6) 0.1 (<0.1, 0.2) 0.1 (0.1, 0.3) 0.0 (–)
N = 6426 N = 6986 N = 1853 N = 7074 N = 3072 N = 2237 N = 7137 N = 546
Country of  manufacturea
 Local 0.0 (–) 24.8 (23.4, 26.2) 29.2 (26.9, 31.5) 15.2 (13.1, 17.6) 3.9 (3.3, 4.7) 9.2 (6.7, 12.6) 1.3 (0.9, 1.9) 0.0 (–)
 India 55.1 (53.1, 57.0) 60.5 (58.2, 62.8) 59.1 (51.7, 66.2) 59.3 (54.1, 64.4) 53.0 (51.3, 54.7) 6.5 (4.7, 8.9) 72.4 (69.3, 75.2) 67.9 (53.1, 79.8)
 China 18.4 (17.3, 19.6) 2.5 (1.8, 3.4) 2.6 (1.5, 4.3) 21.3 (18.0, 25.1) 27.0 (25.2, 28.8) 62.0 (56.9, 66.8) 23.1 (20.5, 25.9) 4.3 (1.8, 9.7)
 European 
Country
19.5 (17.8, 21.3) 7.6 (6.7, 8.7) 8.3 (3.7, 17.5) 2.2 (1.0, 4.8) 14.3 (13.0, 15.7) 22.1 (18.5, 26.3) 3.2 (2.3, 4.3) 27.8 (18.3, 39.8)
 Otherb 7.1 (5.7, 8.9) 4.6 (4.1, 5.1) 0.8 (0.3, 2.5) 2.0 (1.0, 4.1) 1.8 (1.3, 2.4) 0.2 (0.1, 0.7) 0.1 (<0.1, 0.4) <0.1 (<0.1, 0.3)
Registered with 
a National 
Drug Regula-
tory Authority
36.4 (32.8, 40.3) 53.1 (52.0, 54.1) 41.6 (33.5, 50.3) 60.5 (57.6, 63.4) 64.7 (63.4, 66.1) n/a 89.6 (87.8, 91.2) 79.5 (70.9, 86.1)
Countries excluded include: Madagascar (n = 0 products)
n/a Registration list not available in Tanzania for 2014
a  Excluding products with unknown country of manufacture
b  Benin: Cote d’Ivoire, DRC, Morocco, Nigeria, Senegal, Togo; Kinshasa: Vietnam; Katanga: Zambia; Nigeria: Malaysia, Morocco, Pakistan, Senegal, Vietnam; Kenya: 
Bangladesh, USA, Vietnam; Tanzania: Morocco, USA; Uganda: Morocco, USA; Zambia: Kenya
Page 12 of 21ACTwatch Group et al. Malar J  (2017) 16:204 
Non‑QAACT market share
Among anti-malarials dispensed in the public sector, 
market share for non-QAACT increased significantly 
between the first and final survey years in Kinshasa (0.6–
18.0%, p < 0.001), Kenya (1.3–4.7%, p < 0.01) and Zambia 
(0.4–31.6%, p  <  0.001) (Fig.  6). Despite these significant 
increases, non-QAACT market share was low relative to 
the market share for QAACT and non-artemisinin thera-
pies within the public sector in these countries, with the 
exception of Zambia where non-QAACT accounted for 
31.6% of anti-malarials distributed in 2014. Aside from 
Zambia, non-QAACT market share in the public sector 
was highest in Kinshasa at 18.0% in 2015, and was non-neg-
ligible in Nigeria at 5.6% in 2015. Elsewhere, non-QAACT 
market share remained very low over time and was less 
than 1% during the most recent survey in Benin (0.7%), 
Tanzania (0.7%), Uganda (0.6%) and Madagascar (0.5%).
Market share for non-QAACT within the private sec-
tor increased significantly between first and final survey 
rounds in Kinshasa (18.6–42.0%, p < 0.001), Nigeria (5.0–
12.0%, p < 0.01) and Kenya (10.7–20.2%, p < 0.05) (Fig. 7). 
At the time of the most recent survey round, non-QAACT 
market share was highest in Kinshasa, where 42.0% of 
all anti-malarials distributed by the private sector were 
non-QAACT, followed by Katanga (26.7% non-QAACT 
market share). Approximately one in five anti-malari-
als distributed by the private sector were non-QAACT 
in Benin (18.7%), Kenya (20.2%) and Uganda (18.6%). 
Approximately one in ten anti-malarials distributed by 
the private sector were non-QAACT in Nigeria (12.0%) 
and Zambia (8.1%). Non-QAACT market share was much 
lower in the private sectors of Tanzania (5.0%) and Mada-
gascar (0.0%).
For ease of comparing the public and private sector find-
ings, Additional file  3 illustrates a snapshot of the anti-
malarial market share of non-QAACT between these 
sectors. The map illustrates how non-QAACT market 
share was higher in the private sector across all country 
contexts, with the exception of Zambia where 32% of the 
non-QAACT market share was through the public sector, 
compared to 8% in the private sector.
Non-QAACT market share differed across type of pri-
vate sector outlet and tended to be highest among phar-
macies as compared to other private sector outlet types. In 
the most recent survey round, non-QAACT market share 
within pharmacies ranged from one-quarter to one-third 
of all anti-malarial distribution in Kenya (24.6%), Tanza-
nia (28.6%), Uganda (30.3%), Nigeria (39.7%), and Zambia 
(34.9%). Half or more of anti-malarials distributed by phar-
macies were non-QAACT in Katanga (46.6%) and Benin 
(64.7%) (Additional file 4).
Tablets were the most commonly distributed non-
QAACT formulation and accounted for greater than 
75% of the private sector non-QAACT market share 
during the most recent survey round in each country 
(Benin, 89.7%; Kinshasa, 83.0%; Katanga, 88.1%; Kenya, 
88.1%; Nigeria, 79.9%; Tanzania, 89.7%; Uganda, 93.6%; 
Zambia, 81.8%).
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Significant difference in non-QAACT relative market share between first and final survey year: * p<0.05     *** p<0.001
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Fig. 6 Anti-malarial market share within the public sector. Significant difference in non-QAACT relative market share between first and final survey 
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Significant difference in non-QAACT relative market share between first and final survey year: * p<0.05     ** p<0.01     *** p<0.001
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Urban/rural location and private sector outlet type market 
share for non‑QAACT
Figure  8 shows the non-QAACT market share for each 
private sector outlet type and for urban and rural loca-
tions for the most recent survey rounds. Across studies, 
the majority of private sector non-QAACT were dis-
tributed in urban areas. More than 90% of non-QAACT 
were distributed through urban areas in Benin (94.5%), 
Kinshasa (93.3%), Kenya (95.4%), Tanzania (97.2%) and 
Zambia (94.2%). Urban distribution accounted for 86.1% 
of the market in Katanga, 67.4% in Uganda and 60.1% 
in Nigeria. Non-QAACT were distributed primarily by 
pharmacies or drug stores.
Additional file  5 shows the relative market share for 
all anti-malarials according to each private sector outlet 
type and for urban and rural locations for the most recent 
survey rounds. While urban outlets accounted for half or 
more of all anti-malarial distribution in each context with 
the exception of Nigeria (40.8%), urban market share for 
all anti-malarial distribution was lower than urban mar-
ket share for non-QAACT across all contexts.
Discussion
Non-QAACT form a substantial part of the anti-malar-
ial market in sub-Saharan Africa. Of particular concern 
are Nigeria and the DRC, the countries with the high-
est malaria burden in the world [8] and where the private 
sector is responsible for the vast majority of anti-malarial 
distribution [34, 35]. In these two countries, half or more 
of all private sector anti-malarial stocking outlets had non-
QAACT in stock, and non-QAACT accounted for one 
in ten anti-malarials distributed in Nigeria, one in four in 
Katanga DRC, and 40% of all anti-malarial distribution in 
Kinshasa DRC. Furthermore, non-QAACT availability and 
distribution have increased significantly in these countries 
in recent years. High private sector availability and dis-
tribution were noted in other malaria endemic countries, 
including Kenya and Uganda. Private sector availability 
was approximately 40% and non-QAACT accounted for 
one in five anti-malarials distributed in these countries. 
Results from this study provide key insights into non-
QAACT markets with implications for policy and strategy.
What do we know about non‑QAACT on the market 
in sub‑Saharan Africa?
Availability and variety
Overall, non-QAACT were commonly available in the 
private sector and were infrequently available and dis-
tributed within the public sector. Public sector availabil-
ity was typically lower than 10% with notable exceptions 
in the DRC (Kinshasa, 39%) and Zambia (85%). Low 
public sector availability is likely a result of ACT pro-
curements supported with donor funding and therefore 
subject to global quality-assurance standards. In Zambia, 
public sector procurement of non-QAACT from 2013 
to 2014 was supported in part by government funding 
without the restrictions placed on donor-funded com-
modities [36]. Private sector availability of non-QAACT 
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was generally higher than public sector availability with 
the exception of Zambia. While public sector outlets may 
be required to obtain particular drugs that meet certain 
quality standards, quality may not necessarily be a factor 
in private sector procurement decisions. The choice to 
stock a particular anti-malarial is likely to be influenced 
by competition spurred by the stocking trends of neigh-
boring outlets, price, consumer demand, or consumer 
product perceptions [37].
The AMFm, first piloted and administered by the 
Global Fund, was designed to increase access to afford-
able QAACT for private sector first-line buyers. The 
approach increased the availability and market share 
for QAACT in the private sector in countries including 
four of the five AMFm countries studied here: Nigeria, 
Kenya, Tanzania and Uganda [27]. Results from this 
study found higher private sector availability of QAACT 
as compared with non-QAACT in these four countries, 
and in Madagascar (also an AMFm country) and Benin 
(a non-AMFm country with documented private sector 
availability of co-paid ACT due to leakage [38]). This was 
not the case in Zambia and the DRC (also a non-AMFm 
country), where non-QAACT   availability  was higher 
than QAACT in the private sector. One might expect 
AMFm countries to have relatively low non-QAACT 
availability, but this was not always the case. Despite 
improvements in private sector QAACT availability in 
recent years, non-QAACT availability persists and fur-
thermore, has increased in two of the AMFm countries 
with notable improvements in QAACT availability: 
Nigeria and Kenya.
Within the public and private sectors, nine differ-
ent non-QAACT were identified across study coun-
tries, with AL being by far the most common, followed 
by DHA PPQ. AL is the most common first-line ACT in 
each study country, and was one of the first ACT medi-
cines to be developed. A proliferation of non-QA AL 
products, including tablets and suspensions, is there-
fore not surprising. Other non-QAACT are relatively 
new combination therapies and have few, if any manu-
facturers with WHO prequalification or other stringent 
regulatory authority approval. This includes DHA PPQ, 
which in 2015 was manufactured by only one company 
with approval from WHO/Global Fund/EMA (Sigma 
Tau Pharmaceuticals Inc). Numerous brands of non-
QAACT were identified, coming from over 180 distinct 
international manufacturers. Non-QAACT were most 
commonly available in tablet formulation, although sus-
pensions were not uncommon, particularly in the DRC, 
Nigeria and Kenya where they accounted for one-third or 
more of audited non-QAACT products. Suspensions are 
designed and marketed for small children, given the chal-
lenge of administering tablets to infants and children.
Product location
Non-QAACT were usually distributed in urban areas, 
and disproportionately distributed in urban areas relative 
to all anti-malarial distribution. Non-QAACT were typi-
cally sold by pharmacies or drug stores, depending on the 
country context, and these outlet types were most com-
monly located in urban areas. Large urban pharmacies 
and drug stores are likely to have fewer barriers in procur-
ing anti-malarials [39], including fewer supply chain levels 
to navigate [40], allowing for better access to a variety of 
products. In addition, outlets in urban environments typi-
cally serve wealthier customers who may be able to better 
afford the relatively high price of non-QAACT.
Price
One might have expected high relative distribution of 
non-QAACT to be driven by price considerations. How-
ever, results from this study show that non-QA tablets and 
suspensions were typically more expensive than QA AL 
tablets. The relatively low cost of QA first-line treatment 
is likely due to private sector subsidies implemented with 
support from the Global Fund. This copayment mecha-
nism, first piloted as the AMFm, significantly reduced the 
cost of first-line QAACT in Kenya, Nigeria, Tanzania and 
Uganda [27]. This raises the question of why consumers 
would continue to pay more for non-QA products when 
cheaper QAACT are available. As noted earlier, products 
were primarily distributed by pharmacies and drug stores 
in urban areas, likely reflecting higher purchasing power 
of urban consumers. The phenomenon may be due in 
part to perceptions that higher prices are associated with 
higher quality, and/or consumer beliefs that subsidized 
ACT are of relatively poor quality [41], but additional 
research is needed to parse out purchasing determinants 
and consumer choice related to both price and tablet for-
mulation. A better understanding of provider and con-
sumer demand for QAACT and non-QAACT will be 
important for developing strategies to promote use of QA 
over non-QA products.
Implications for anti‑malarial drug policy and strategy
Addressing the availability and distribution of non-
QAACT in sub-Saharan Africa will require strategies that 
target all levels of the anti-malarial supply and distribution 
chain. Figure  9 summarizes opportunities for reducing 
non-QAACT product penetration by targeting key ele-
ments of the supply chain: manufacturers, national regis-
tration systems, wholesalers and retailers, and consumers.
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Manufacturers
This study defined QAACT according to global standards 
and prequalification/approval from the WHO, Global 
Fund, or EMA. During the most recent round of data 
collection in 2014/2015, only 12 manufacturers met QA 
standards and appeared on approved/prequalified anti-
malarial drug lists for the WHO, the Global Fund, and/or 
the EMA. In contrast, 185 manufacturers of non-QAACT 
were identified across the eight study countries. For some 
of the products currently classified as non-QAACT, there 
may be potential for these products to achieve QA status 
by extending support to manufacturers to meet require-
ments for prequalification.
While the WHO PQP provides guidance and support 
for applicants, gaining approval from an external author-
ity is a technically challenging, rigorous process that 
can take a minimum of three years. Fees for the applica-
tion, in-country product registration, and facility GMP 
inspection can exceed $100,000 [42]. Combination ther-
apies, such as those indicated for malaria, have particu-
larly complex testing and regulatory requirements for 
approval. Even after achieving QA status, products are 
subject to periodic testing, monitoring, and re-approval. 
For small or newly established in-country manufactur-
ers with limited resources, the barriers to this assess-
ment and approval process are often prohibitive [23, 26]. 
Depending on the country, quality assurance activities 
may or may not be well-supported by the NDRA, the 
country-level drug licensing, control, and post-market-
ing surveillance body [21]. Supporting manufacturers to 
obtain GMP certification and apply for WHO PQP status 
could leverage existing resources to increase the presence 
of quality-assured drugs in malaria-endemic countries. 
Developing and enforcing national regulations for 
manufacturing quality would further ensure the produc-
tion and supply of quality drugs. In the case of manufac-
turers who have not yet reached global quality standards, 
working to expand capacity for quality improvement may 
be most appropriate. Yet, maintaining high-quality and 
sustainable production in SSA presents its own chal-
lenges. The unstable energy supply, lack of technical 
specialists, and unpredictable transport systems charac-
teristic of some SSA countries increase the likelihood of 
supply chain failures and can cause production costs to 
balloon [43, 44]. These challenges should be taken into 
consideration when designing and supporting viable, 
high-quality manufacturing sites.
It is also important to note that non-QAACT available 
in non-tablet formulations are unlikely to be eligible to 
obtain QA status. Suspensions involve reconstitution or 
volume measurement and this may inhibit accurate dos-
ing. Additionally, once opened and reconstituted, the 
stability and hygiene of suspension formulations can no 
longer be guaranteed. As such, ACT suspensions are not 
included on the WHO pre-qualification or Global Fund 
procurement lists. A preferred pediatric-friendly alterna-
tive is the use of dispersible tablets which have been avail-
able for QA AL since 2009  [45, 46, 47]. There is need for 
additional information on consumer and provider prefer-
ences for ACT suspensions in the context of availability 
of dispersible tablets. Results from this study suggest that 
preference for suspensions may be driving availability in 
both private and public sectors in some countries.
National registration systems
Promoting the use of QAACT and discouraging the 
use of non-QAACT can be addressed at the national 
level, and can be facilitated through exclusion of non 
Fig. 9 Opportunities for reducing non-QA product penetration in the supply chain
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quality-assured products from national registration lists 
and government procurements. NDRA lists can be used 
to regulate private sector outlets by promoting products 
on the list and implementing communication, regulation 
and penalties regarding the importation and sale of non-
registered products. However, NDRA lists in most of the 
study countries are currently not well-suited to this pur-
pose as they are generally not aligned with global qual-
ity recommendations and national treatment guidelines. 
Results from this study found that typically, more than 
half of non-QAACT available were found on national-
registration lists. Aligning national drug registration 
with global quality assurance standards may prove chal-
lenging given the need for multi-sectoral collabora-
tion towards this effort. Where NDRA registration lists 
cannot be aligned with national or global standards for 
quality, national malaria control programs may need to 
devise independent approved lists of anti-malarials for 
training, supervision, communication and promotion 
purposes.
Active efforts to remove non-QAACT from anti-
malarial markets could prove challenging. Efforts may 
not be readily acceptable to regulatory authorities and 
public and private buyers that have existing agree-
ments in place with certain manufacturers or import-
ers. Efforts to stop the importation and distribution of 
non-QAACT would also have economic consequences 
for manufacturers themselves. Local manufacturers, 
which were not uncommon in the DRC and Nigeria, 
may be particularly vulnerable to these potential eco-
nomic impacts. Furthermore, a focus on removing 
non-QAACT must not preclude attention to removal 
of banned oral artemisinin monotherapies and ineffec-
tive non-artemisinin therapies that persist on the mar-
ket to varying degrees in each of the countries included 
in this study [48]. Removal of these products may be of 
more imminent concern in certain areas than removal 
of non-QAACT, and thus, may need to be prioritized 
for regulatory attention. Public health policy and regu-
lation shifts with respect to non-QAACT would require 
strategies that take all of these political and economic 
realities into account.
Wholesalers and retailers
Results from this study suggest the potential to sub-
stantially improve anti-malarial quality through greater 
private sector engagement and regulation to align pri-
vate sector practices with national guidelines and qual-
ity-assurance standards. Private sector engagement to 
increase access to quality products can be facilitated 
in a variety of ways at the wholesaler and retailer level. 
Wholesalers, ranging from international importers 
to local merchandisers, can influence drug quality by 
restricting purchases to GMP-certified manufacturers 
and by monitoring products for non quality-assured 
drug removal. Improving private provider practices 
will also be an essential part of efforts to improve drug 
quality in the market. Strategies to improve provider 
practices in the private sector have included train-
ing, supervision and regulation under accreditation 
or other quality assurance programs. These programs 
are typically designed and implemented to promote 
the use of appropriate assessment, diagnostic/testing, 
referral, and treatment behaviors, including use of the 
first-line treatment for uncomplicated malaria, but they 
also provide an important opportunity for education 
and enforcement around non-QAACT. For example, a 
multi-pronged market intervention in Cambodia facili-
tated access to quality products through a diagnosis and 
treatment training for providers and through medical 
detailing that promoted quality assurance [49]. Tan-
zania’s Accredited Drug Dispensing Outlets (ADDO) 
pilot programme, which aimed to develop the capacity 
of pharmacy staff to provide quality drugs, was associ-
ated with a 13-fold reduction in unregistered medicines 
(from 26% at baseline to 2% after ADDO implementa-
tion) [50, 51]. Other private sector engagement initia-
tives, such as Nigeria’s patent medicines vendor training 
programme [52]  and Kenya’s drug shop and clinic fran-
chising programme  [53, 54, 55, 56], have also led to 
quality improvement.
Results from this study show that strategies for pri-
vate sector engagement and improved regulation can 
be highly targeted. The problem of non-QAACT avail-
ability and distribution is primarily in urban areas and 
is concentrated in many countries among either phar-
macies or drug stores, though in other settings, private 
for-profit health facilities are also key outlets. Private 
sector engagement and regulatory enforcement focused 
on large urban outlets could be highly effective in remov-
ing these medicines from the market at national level. 
Private sector cooperation with law enforcement will 
be key in supporting these efforts. Conducting periodic 
site inspections to remove poor-quality products from 
the market and levying penalties for those who enable 
poor quality medicines to enter the market will help to 
improve overall market quality.
It should be noted that measures to remove non-
QAACT from anti-malarial markets have the potential 
to reduce overall access to ACT. In the countries studied 
here, this is a risk primarily in the DRC, where availabil-
ity of QAACT remains very low. In other study coun-
tries, particularly those with improved access to QAACT 
through public and private sector subsidy mechanisms, 
there would appear to be little to no risk in removing non 
quality-assured products from the shelves.
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Consumers
The potential to stimulate demand for QAACT at the 
expense of non quality-assured medicines hinges on 
the ability of providers and consumers to identify and 
demand QA medicines. One approach to branding 
QAACT so that communications campaigns can pro-
mote their use is to use an identifying logo or quality 
seal. A green leaf logo placed on product packaging and 
promoted in mass media campaigns was used to identify 
co-paid QAACT under the AMFm and the subsequent 
Private Sector Copayment Mechanism. Awareness of the 
leaf, as evidenced by increases in uptake and availability 
of ACT, was well documented in countries that imple-
mented mass media campaigns to promote the brand 
[57–59]. At the national level, a logo indicating quality 
and national approval could be applied to all QAACT 
and this logo could be used in campaigns to promote 
consumer trust and demand for these products.
An alternative to a quality logo is the use of mobile 
authentication systems (MAS). With MAS, scratch 
codes embedded on product packaging allow consum-
ers to authenticate the product at the point of purchase 
via text message. Countries like Nigeria legally require 
all anti-malarials to carry a verifiable MAS code, which 
is only given to products registered with the national 
drug authority [60]. However, drug registration status 
may not be synonymous with drug quality and, until this 
is the case, MAS may provide a false sense of assurance 
for buyers. While mobile authentication has been useful 
for detecting falsified products and ensuring purchase 
of legitimate brands or nationally-registered products, it 
has yet to be used exclusively for product quality-assur-
ance, such as tagging of WHO prequalified products.
Other strategies to improve anti‑malarial quality
The above strategies are key for reducing the penetra-
tion of non-QAACT in the market. However, they are 
not sufficient on their own. They must be supported by 
additional, complementary measures to improve anti-
malarial quality such as promoting GMP, improving drug 
testing capacity, encouraging proper drug transport and 
storage, and working with law enforcement to fight fal-
sification. Efforts to increase the share of QAACT avail-
able and distributed to consumers are equally important, 
and engaging the private sector in these efforts will be 
paramount.
Many of the strategies discussed will rely on a strong 
NDRA. Strengthening regulatory capacity is also key 
for meeting external mandates for quality approval. 
NDRAs in SSA suffer from a host of common structural 
deficiencies, including a lack of technical guidelines, 
a chronic shortage of qualified medicine and facility 
assessors, limited legislative influence, regular use of 
adverse event-based response rather than risk-based 
quality monitoring systems, a general lack of account-
ability, and poor regulation enforcement [21]. Some 
countries have already taken steps towards implement-
ing the strategies discussed. For example, Nigeria’s 
National Food and Drug Administration has undertaken 
drug screening through deployment of drug-authen-
ticating Raman spectrometers [61]. In East Africa, six 
countries have banded together to improve drug regula-
tion through the WHO/East African Community (EAC) 
Medicines Regulatory Harmonization Project. Other 
countries in Southeast Asia have coordinated with 
INTERPOL, customs authorities, and police to take 
action against poor quality medicines [4]. While efforts 
have been made in the public sector to ensure availabil-
ity and distribution of QAACT, more effort is needed to 
address the issue in the private sector. Long-term qual-
ity improvement for anti-malarials will require a cross-
sector, multiple-strategy approach.
Study strengths and limitations
ACTwatch implements a rigorous, standardized meth-
odology across study countries and over time. The outlet 
survey study design entails a full census of all outlets with 
the potential to distribute anti-malarials within selected 
clusters, and a full audit of all available products, thus 
constituting a study of the total anti-malarial market. 
The current findings are strengthened by measurement 
in multiple countries within west and central, east, and 
southern Africa with repeat cross-sections over time. 
Despite the strengths of the outlet survey design, certain 
limitations exist, including the potential that providers 
misreported stocking information or had poor recall, the 
cross-sectional nature of the surveys, and the possibil-
ity that in practice, certain outlets may have been missed 
despite the full census. These and other limitations are 
described extensively elsewhere [32, 33]. Specific to this 
study, surveys were powered to detect significant differ-
ences in availability of QAACT over time, whereas this 
study reported on non-QAACT indicators and there-
fore may not have had the power to detect meaningful 
change. In addition, chemical drug quality testing and 
analysis were beyond the scope of this project. Generaliz-
ability outside of the eight study countries is also likely to 
be limited, given that this study shows that non-QAACT 
product markets differ across countries, even within the 
same region.
Relying only on details of medicines recorded on 
audit sheets to define quality-assured status has limita-
tions as any recording errors could lead to misclassifica-
tion. Despite the intensive data collector training in this 
area, such errors do sometimes occur, for example, due 
to confusion over whether the country of manufacture 
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or country of manufacturer headquarters should be 
recorded. Due to strict classification criteria, requiring 
all product fields to match those of global quality stand-
ard lists, a small proportion of products may have been 
incorrectly classified as a non-QAACT when they were 
in fact quality-assured.
Conclusion
Non-QAACT are available and distributed to varying 
degrees in high malaria burden countries, primarily within 
the private sector and in urban areas. Non-QAACT avail-
ability and distribution were documented in settings 
with low private sector availability of QAACT including 
the DRC, as well as in countries with high private sec-
tor QAACT availability including Nigeria, Kenya and 
Uganda. The market is diverse, with multiple combina-
tions from various manufacturers available in tablet and 
non-tablet formulations. Addressing the availability and 
distribution of non-QAACT will require effective pri-
vate sector engagement and evidence-based strategies 
to address provider and consumer demand and supply. 
Given the variation in non-QAACT markets observed 
across eight countries, the design and implementation of 
efforts to limit registration, importation and distribution 
of non-QAACT must be tailored to the country context, 
and will no doubt involve addressing complex and chal-
lenging aspects of registration, private sector regulation, 
local manufacturing and drug importation. However, tak-
ing action to address non quality-assured medicine avail-
ability and use may be critical not only to patient health 
and safety, but to effective malaria control and protection 
of artemisinin and partner drug efficacy.
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